PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
3.56%
Cash & equivalents growing 3.56% while AGEN's declined -13.79%. Peter Lynch would see this as a sign of superior liquidity management.
-100.00%
Short-term investments yoy growth below half of AGEN's 133.20%. Michael Burry might see potential liquidity risk. Investigate alternative capital uses or constraints.
3.51%
Below half of AGEN's -13.79%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.27%
Below half of AGEN's -11.89%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
11.32%
Below half AGEN's 95.55%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of AGEN's 5.42%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-18.41%
Below half of AGEN's 72.68%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Below half of AGEN's -0.16%. Michael Burry sees a potential red flag for stagnation or capital shortage.
65.90%
1.25-1.5x AGEN's 45.20%. Martin Whitman sees potential reliance on supplier financing. Verify liquidity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
126.86%
Less than half of AGEN's -10.40%. David Dodd sees fewer expansions in other current obligations.
114.06%
Above 1.5x AGEN's 2.29%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
114.06%
Above 1.5x AGEN's 3.54%. Michael Burry sees a potential leverage warning sign.
5.13%
Above 1.5x AGEN's 2.06%. Michael Burry suspects heavy new equity expansion or dilution.
-6.19%
≥ 1.5x AGEN's -2.04%. David Dodd sees higher yoy retained profits than competitor.
-12.13%
Less than half of AGEN's -54.18%. David Dodd sees fewer intangible or market-driven swings than competitor.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to AGEN's zero value, indicating worse performance.
-4.02%
Below half AGEN's -8.12%. Michael Burry sees potential underperformance in building shareholder capital.
6.14%
Below half AGEN's -0.16%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Below half AGEN's 133.20%. Michael Burry suspects major underinvestment or forced divestment.
No Data
No Data available this quarter, please select a different quarter.
-2.49%
Less than half of AGEN's 35.32%. David Dodd sees better deleveraging or stronger cash buildup than competitor.